Sangamo Therapeutics Inc.’s shares sank 27 percent after the company’s gene-editing drug failed to show promise in an early-stage trial testing for patients with ultra-rare disorders.
Pixium Vision announced that the bioelectronics company’s subretinal PRIMA system met the endpoints of the feasibility study, at interim 6 months follow-up after implantation and rehabilitation for patients with advanced dry age-related macular degeneration (AMD).
Researchers at Johns Hopkins University, the University of California, San Diego (UCSD), and the National Institute of Mental Health grew retinas in Petri dishes and discovered fundamental factors involved in the development of vision and color vision.
An interim analysis of an early-stage trial showed that ProQR Therapeutics NV’s experimental treatment for a rare form of childhood blindness improved vision.
Clearside Biomedical Inc. said the drug developer’s treatment helped improve vision in patients with fluid buildup in the eye in a late-stage study.
Eye doctors who had braced themselves for at least a few patients after a dazzling solar eclipse swept the United States cautiously exhaled, with some hospitals reporting zero cases of damaged vision so far.
For the first time, EPGL reveals the “Omega” contact lens under development with InWith Corp. The patent pending “Omega” is designed to correct vision anytime by changing the curvature of the lenses on-demand, via smart phone or other mobile devices.
People with very poor vision may benefit from using a device that recognizes faces, money and text, a small study suggests.
Two Indian states have put sales of Swiss drugmaker Roche’s blockbuster drug Avastin on hold, officials said on Tuesday, after it hampered the vision of 15 patients who used it for a condition it is not officially meant to treat. Avastin is a cancer drug but is often used by doctors to treat vision […]
Drug developer Spark Therapeutics Inc said its lead experimental drug helped improve the vision of patients with a type of inherited eye disorder, in a late stage study. The drug, SPK-RPE65, met the main goal of improving vision and sensitivity to light in patients who were previously at the risk of complete blindness, the company […]